TransMedics Group (NASDAQ:TMDX) PT Raised to $130.00 at TD Cowen

TransMedics Group (NASDAQ:TMDX) had its price objective lifted by equities researchers at TD Cowen from $100.00 to $130.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price objective would indicate a potential upside of 4.47% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Oppenheimer lifted their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. Canaccord Genuity Group boosted their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. Morgan Stanley upped their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $124.44 on Wednesday. The stock has a market cap of $4.07 billion, a P/E ratio of -366.00 and a beta of 1.87. The stock has a 50 day simple moving average of $84.64 and a 200 day simple moving average of $76.26. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $124.52.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.08) EPS. Research analysts anticipate that TransMedics Group will post -0.14 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the company’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the company’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 102,078 shares of company stock worth $8,691,221. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group during the 1st quarter valued at about $30,000. Fidelis Capital Partners LLC bought a new stake in shares of TransMedics Group during the 1st quarter valued at about $35,000. Cutler Group LLC CA boosted its position in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. RiverPark Advisors LLC bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $60,000. Finally, First Horizon Advisors Inc. boosted its position in shares of TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.